Timothy Moseley
Company: Direct Biologics
Job title: Chief Scientific Officer
Bio:
Tim Moseley is the Chief Scientific Officer for Direct Biologics and has a strong 30 year academic and industry background in the regenerative medicine space. He received his PhD from the University of California, Davis in Cellular and Developmental Biology in the Department of Orthopaedic Surgery, where he created the UC Davis Center for Tissue Regeneration and Repair (CTRR).
Tim moved into the biotech industry managing the preclinical use of adipose-derived stem cells at Cytori Therapeutics, Inc. and then as the Divisional Scientist of Biologics at NuVasive, Inc. managing the clinical use of cellular bone grafts. He cofounded Paisley Laboratories, where he developed a mesenchymal stromal cell secretome product as their Chief Scientific Officer. Direct Biologics acquired Paisley Laboratories in 2018, and Tim has been leading their science and manufacturing effort of bringing their life changing investigational drug to market. Tim has published research in many peer-reviewed publications related to stem cells, general orthopaedics, and regenerative medicine.
Seminars:
A Non-Conventional Pathway to Commercialize an EV Therapeutic 9:30 am
MSC secretome: Cell therapy without the cells Navigating Direct Biologics’ pathway to phase III clinical trial Leveraging nature’s mechanism of action for disease mitigation NEW DATA!Read more
day: Conference Day One
Biopharma Leaders Panel Discussion: Unlocking the Next Wave of Safe & Efficient Exosome-Based Therapeutics Towards Clinical & Commercial Reality 1:30 pm
This is your chance to hear from pioneering executive leaders from the exosome and extra-cellular vesicle community who will discuss their strategies, challenges, and future perspectives for exosome technology and clinically relevant therapeutic applications. What are the future opportunities, promising targets, and applications on the horizon for exosomes to achieve clinical success? What can we…Read more
day: Conference Day One